Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin

Cell Metabolism

Volumn 24, Issue 5, 2016, Pages 716-727

  Gui, Dan Y ^a   Sullivan, Lucas B ^a   Luengo, Alba ^a   Hosios, Aaron M ^a   Bush, Lauren N ^a   Gitego, Nadege ^a   Davidson, Shawn M ^a   Freinkman, Elizaveta ^b   Thomas, Craig J ^c   Vander Heiden, Matthew G ^a,d  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

aspartate; biguanide; cancer metabolism; complex I; drug sensitivity; metformin; mitochondria; NAD+ NADH ratio

Indexed keywords

ASPARTIC ACID; METFORMIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); PYRUVIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER MORTALITY; CELL METABOLISM; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG SENSITIVITY; ENZYME INHIBITION; HOMEOSTASIS; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGENERATION; TISSUE CULTURE; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; HUMAN; METABOLISM; MITOCHONDRION; NEOPLASM; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ANIMALS; ASPARTIC ACID; CELL LINE, TUMOR; CELL PROLIFERATION; ELECTRON TRANSPORT COMPLEX I; HOMEOSTASIS; HUMANS; METFORMIN; MICE, NUDE; MITOCHONDRIA; NAD; NEOPLASMS; PYRUVIC ACID; TUMOR MICROENVIRONMENT;

EID: 84994671524     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2016.09.006     Document Type: Article

References (54)

1. Andrzejewski, S., Gravel, S.P., Pollak, M., St-Pierre, J., Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer Metab., 2, 2014, 12.
2. Bai, P., Cantó, C., Oudart, H., Brunyánszki, A., Cen, Y., Thomas, C., Yamamoto, H., Huber, A., Kiss, B., Houtkooper, R.H., et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab. 13 (2011), 461–468.
3. Birsoy, K., Sabatini, D.M., Possemato, R., Untuning the tumor metabolic machine: targeting cancer metabolism: a bedside lesson. Nat. Med. 18 (2012), 1022–1023.
4. Birsoy, K., Possemato, R., Lorbeer, F.K., Bayraktar, E.C., Thiru, P., Yucel, B., Wang, T., Chen, W.W., Clish, C.B., Sabatini, D.M., Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature 508 (2014), 108–112.
5. Birsoy, K., Wang, T., Chen, W.W., Freinkman, E., Abu-Remaileh, M., Sabatini, D.M., An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis. Cell 162 (2015), 540–551.
6. Bridges, H.R., Jones, A.J., Pollak, M.N., Hirst, J., Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem. J. 462 (2014), 475–487.
7. Buzzai, M., Jones, R.G., Amaravadi, R.K., Lum, J.J., DeBerardinis, R.J., Zhao, F., Viollet, B., Thompson, C.B., Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 67 (2007), 6745–6752.
8. Cantó, C., Houtkooper, R.H., Pirinen, E., Youn, D.Y., Oosterveer, M.H., Cen, Y., Fernandez-Marcos, P.J., Yamamoto, H., Andreux, P.A., Cettour-Rose, P., et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 15 (2012), 838–847.
9. Chen, L., Pawlikowski, B., Schlessinger, A., More, S.S., Stryke, D., Johns, S.J., Portman, M.A., Chen, E., Ferrin, T.E., Sali, A., et al. Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. Pharmacogenet. Genomics 20 (2010), 687–699.
10. Chen, E.C., Liang, X., Yee, S.W., Geier, E.G., Stocker, S.L., Chen, L., Giacomini, K.M., Targeted disruption of organic cation transporter 3 attenuates the pharmacologic response to metformin. Mol. Pharmacol. 88 (2015), 75–83.
11. Cuyàs, E., Fernández-Arroyo, S., Corominas-Faja, B., Rodríguez-Gallego, E., Bosch-Barrera, J., Martin-Castillo, B., De Llorens, R., Joven, J., Menendez, J.A., Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. Oncotarget 6 (2015), 12279–12296.
12. Davidson, S.M., Papagiannakopoulos, T., Olenchock, B.A., Heyman, J.E., Keibler, M.A., Luengo, A., Bauer, M.R., Jha, A.K., O'Brien, J.P., Pierce, K.A., et al. Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer. Cell Metab. 23 (2016), 517–528.
13. Dell'Aglio, D.M., Perino, L.J., Kazzi, Z., Abramson, J., Schwartz, M.D., Morgan, B.W., Acute metformin overdose: examining serum pH, lactate level, and metformin concentrations in survivors versus nonsurvivors: a systematic review of the literature. Ann. Emerg. Med. 54 (2009), 818–823.
14. El-Mir, M.Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., Leverve, X., Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 275 (2000), 223–228.
15. Evans, J.M., Donnelly, L.A., Emslie-Smith, A.M., Alessi, D.R., Morris, A.D., Metformin and reduced risk of cancer in diabetic patients. BMJ 330 (2005), 1304–1305.
16. Fang, E.F., Scheibye-Knudsen, M., Brace, L.E., Kassahun, H., SenGupta, T., Nilsen, H., Mitchell, J.R., Croteau, D.L., Bohr, V.A., Defective mitophagy in XPA via PARP-1 hyperactivation and NAD(+)/SIRT1 reduction. Cell 157 (2014), 882–896.
17. Fendt, S.M., Bell, E.L., Keibler, M.A., Davidson, S.M., Wirth, G.J., Fiske, B., Mayers, J.R., Schwab, M., Bellinger, G., Csibi, A., et al. Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res. 73 (2013), 4429–4438.
18. Foretz, M., Guigas, B., Bertrand, L., Pollak, M., Viollet, B., Metformin: from mechanisms of action to therapies. Cell Metab. 20 (2014), 953–966.
19. Gandini, S., Puntoni, M., Heckman-Stoddard, B.M., Dunn, B.K., Ford, L., DeCensi, A., Szabo, E., Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev. Res. (Phila.) 7 (2014), 867–885.
20. Gomes, A.P., Price, N.L., Ling, A.J., Moslehi, J.J., Montgomery, M.K., Rajman, L., White, J.P., Teodoro, J.S., Wrann, C.D., Hubbard, B.P., et al. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell 155 (2013), 1624–1638.
21. Goswami, S., Yee, S.W., Stocker, S., Mosley, J.D., Kubo, M., Castro, R., Mefford, J.A., Wen, C., Liang, X., Witte, J., et al. Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin. Clin. Pharmacol. Ther. 96 (2014), 370–379.
22. Graham, G.G., Punt, J., Arora, M., Day, R.O., Doogue, M.P., Duong, J.K., Furlong, T.J., Greenfield, J.R., Greenup, L.C., Kirkpatrick, C.M., et al. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet. 50 (2011), 81–98.
23. Gravel, S.P., Hulea, L., Toban, N., Birman, E., Blouin, M.J., Zakikhani, M., Zhao, Y., Topisirovic, I., St-Pierre, J., Pollak, M., Serine deprivation enhances antineoplastic activity of biguanides. Cancer Res. 74 (2014), 7521–7533.
24. Griss, T., Vincent, E.E., Egnatchik, R., Chen, J., Ma, E.H., Faubert, B., Viollet, B., DeBerardinis, R.J., Jones, R.G., Metformin antagonizes cancer cell proliferation by suppressing mitochondrial-dependent biosynthesis. PLoS Biol., 13, 2015, e1002309.
25. Hardie, D.G., Molecular pathways: is AMPK a friend or a foe in cancer?. Clin. Cancer Res. 21 (2015), 3836–3840.
26. He, L., Wondisford, F.E., Metformin action: concentrations matter. Cell Metab. 21 (2015), 159–162.
27. He, X., Esteva, F.J., Ensor, J., Hortobagyi, G.N., Lee, M.H., Yeung, S.C., Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann. Oncol. 23 (2012), 1771–1780.
28. Huang, X., Wullschleger, S., Shpiro, N., McGuire, V.A., Sakamoto, K., Woods, Y.L., McBurnie, W., Fleming, S., Alessi, D.R., Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem. J. 412 (2008), 211–221.
29. Jiralerspong, S., Palla, S.L., Giordano, S.H., Meric-Bernstam, F., Liedtke, C., Barnett, C.M., Hsu, L., Hung, M.C., Hortobagyi, G.N., Gonzalez-Angulo, A.M., Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J. Clin. Oncol. 27 (2009), 3297–3302.
30. King, M.P., Attardi, G., Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 246 (1989), 500–503.
31. Kordes, S., Pollak, M.N., Zwinderman, A.H., Mathôt, R.A., Weterman, M.J., Beeker, A., Punt, C.J., Richel, D.J., Wilmink, J.W., Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 16 (2015), 839–847.
32. Lee, J.H., Kim, T.I., Jeon, S.M., Hong, S.P., Cheon, J.H., Kim, W.H., The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int. J. Cancer 131 (2012), 752–759.
33. Lewis, C.A., Parker, S.J., Fiske, B.P., McCloskey, D., Gui, D.Y., Green, C.R., Vokes, N.I., Feist, A.M., Vander Heiden, M.G., Metallo, C.M., Tracing compartmentalized NADPH metabolism in the cytosol and mitochondria of mammalian cells. Mol. Cell 55 (2014), 253–263.
34. Li, W., Saud, S.M., Young, M.R., Chen, G., Hua, B., Targeting AMPK for cancer prevention and treatment. Oncotarget 6 (2015), 7365–7378.
35. Luengo, A., Sullivan, L.B., Heiden, M.G., Understanding the complex-I-ty of metformin action: limiting mitochondrial respiration to improve cancer therapy. BMC Biol., 12, 2014, 82.
36. Madera, D., Vitale-Cross, L., Martin, D., Schneider, A., Molinolo, A.A., Gangane, N., Carey, T.E., McHugh, J.B., Komarck, C.M., Walline, H.M., et al. Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3. Cancer Prev. Res. (Phila.) 8 (2015), 197–207.
37. Madiraju, A.K., Erion, D.M., Rahimi, Y., Zhang, X.M., Braddock, D.T., Albright, R.A., Prigaro, B.J., Wood, J.L., Bhanot, S., MacDonald, M.J., et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510 (2014), 542–546.
38. Mayers, J.R., Vander Heiden, M.G., Famine versus feast: understanding the metabolism of tumors in vivo. Trends Biochem. Sci. 40 (2015), 130–140.
39. Memmott, R.M., Mercado, J.R., Maier, C.R., Kawabata, S., Fox, S.D., Dennis, P.A., Metformin prevents tobacco carcinogen–induced lung tumorigenesis. Cancer Prev. Res. (Phila.) 3 (2010), 1066–1076.
40. Merker, M.P., Audi, S.H., Bongard, R.D., Lindemer, B.J., Krenz, G.S., Influence of pulmonary arterial endothelial cells on quinone redox status: effect of hyperoxia-induced NAD(P)H:quinone oxidoreductase 1. Am. J. Physiol. Lung Cell. Mol. Physiol. 290 (2006), L607–L619.
41. Nies, A.T., Hofmann, U., Resch, C., Schaeffeler, E., Rius, M., Schwab, M., Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs). PLoS ONE, 6, 2011, e22163.
42. Owen, M.R., Doran, E., Halestrap, A.P., Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 348 (2000), 607–614.
43. Pernicova, I., Korbonits, M., Metformin–mode of action and clinical implications for diabetes and cancer. Nat. Rev. Endocrinol. 10 (2014), 143–156.
44. Pillai, J.B., Isbatan, A., Imai, S., Gupta, M.P., Poly(ADP-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity. J. Biol. Chem. 280 (2005), 43121–43130.
45. Pirinen, E., Cantó, C., Jo, Y.S., Morato, L., Zhang, H., Menzies, K.J., Williams, E.G., Mouchiroud, L., Moullan, N., Hagberg, C., et al. Pharmacological inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle. Cell Metab. 19 (2014), 1034–1041.
46. Pollak, M., Overcoming drug development bottlenecks with repurposing: repurposing biguanides to target energy metabolism for cancer treatment. Nat. Med. 20 (2014), 591–593.
47. Schöckel, L., Glasauer, A., Basit, F., Bitschar, K., Truong, H., Erdmann, G., Algire, C., Hägebarth, A., Willems, P.H., Kopitz, C., et al. Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth. Cancer Metab., 3, 2015, 11.
48. Shackelford, D.B., Abt, E., Gerken, L., Vasquez, D.S., Seki, A., Leblanc, M., Wei, L., Fishbein, M.C., Czernin, J., Mischel, P.S., et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 23 (2013), 143–158.
49. Shu, Y., Sheardown, S.A., Brown, C., Owen, R.P., Zhang, S., Castro, R.A., Ianculescu, A.G., Yue, L., Lo, J.C., Burchard, E.G., et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest. 117 (2007), 1422–1431.
50. Sullivan, L.B., Gui, D.Y., Hosios, A.M., Bush, L.N., Freinkman, E., Vander Heiden, M.G., Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells. Cell 162 (2015), 552–563.
51. Wang, B., Hasan, M.K., Alvarado, E., Yuan, H., Wu, H., Chen, W.Y., NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response. Oncogene 30 (2011), 907–921.
52. Wheaton, W.W., Weinberg, S.E., Hamanaka, R.B., Soberanes, S., Sullivan, L.B., Anso, E., Glasauer, A., Dufour, E., Mutlu, G.M., Budigner, G.S., et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife, 3, 2014, e02242.
53. Zhang, X., Fryknäs, M., Hernlund, E., Fayad, W., De Milito, A., Olofsson, M.H., Gogvadze, V., Dang, L., Påhlman, S., Schughart, L.A., et al. Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments. Nat. Commun., 5, 2014, 3295.
54. Zhu, N., Zhang, Y., Gong, Y.I., He, J., Chen, X., Metformin and lung cancer risk of patients with type 2 diabetes mellitus: a meta-analysis. Biomed. Rep. 3 (2015), 235–241.